Key facts
- It has raised $4.9M; the latest was Early Stage VC ($2.8M) in Sep 2025.
- Notable investors include Oost NL, Lumo Labs, Eurostars, Health Innovations, TNO (Commercial Services).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Aiosyn
- ·The full record, as it builds
Funding rounds
No funding rounds for Aiosyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aiosyn
Developer of a medical analysis platform designed to accelerate the adoption of artificial intelligence in pathology diagnostics. The company's platform provides synergy between pathologists and artificial intelligence and offers computational pathology technology to facilitate informed decision-making in both drug development and clinical diagnostics, enabling pathologists to work more accurately and efficiently in diagnostics and to improve the survival chances of cancer patients worldwide.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Founded
- 2021
- Employees
- 14
- Website
- aiosyn.com/
- Ownership
- Privately Held (backing)
Aiosyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aiosyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aiosyn in its N-PORT filings yet. We sweep new filings monthly.